Figure 2

DNA methylation and serum levels of IGFBP1 according to family history of diabetes. Compared with those without a family history of diabetes ( FHD) (0), non-diabetic control subjects with FHD (1) had similar IGFBP1 DNA methylation levels (16.9% vs. 17.0%, P = 0.895, A) but significantly lower serum protein levels (19 vs. 25 μg/L, P = 0.018) (B). Newly diagnosed type 2 diabetes patients with FHD had significantly increased IGFBP1 DNA methylation levels (20.3% vs. 18.6%, P = 0.014) (A), higher glucose (8.1 vs. 6.5 mmol/l, P = 0.007) and insulin (153.6 vs. 118.8 pmol/l, P = 0.022) levels compared to patients without FHD (B). There were no differences in levels of IGFBP1 DNA methylation, serum IGFBP-1, glucose or insulin between treated type 2 diabetes patients with and without FHD. P value: * < 0.05. FHD, family history of diabetes; NGT, normal glucose tolerance; T2D, type 2 diabetes.